Registry models link prescribing patterns to clinic and medication context
Source check: Source checked. Not independent scientific confirmation.
Finding: In 864,339 registry patients with atrial fibrillation, an enhanced XGBoost model identified documented anticoagulant prescriptions with a test AUROC of0.811. Clinic-location income, clinic size and region contributed permutation importance alongside age and concurrent medications. These are descriptive prescribing-pattern associations, not causal socioeconomic effects.
Technology: XGBoost; random forest; penalized logistic regression
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Fitted classifiers map patient and clinic features to documented prescriptions. Permutation analysis on the test set identifies model-used contextual information beyond a clinical risk-score feature set.
- Test and result
- PINNACLE records from January2017–June2018 were split80:20 by patient; hyperparameters used fivefold training cross-validation. Prescription status and inputs came from the most recent three-month record window.
- Limitation / still unknown
- Income is a clinic-ZIP-code mean, not each patient’s household income. Concurrent medications and INR can reflect prescribing or monitoring consequences rather than causes; same-clinic records can occur on both sides of the random split. Missing fields and voluntary outpatient practices limit representativeness. The CHA2DS2-VASc comparator is a clinical stroke-risk score, not a prescription model; no causal disparity, guideline benefit or improved treatment outcome is established.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10041076/ · https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/PMC10041076/unicode
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Official primary BioC original article sections: Registry/outcome/feature Methods;patient split/tuning;test permutation-importance Results and limitations; no laboratory-method validation.
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.